Search

Your search keyword '"Maruyama-Sakurai, Keiko"' showing total 25 results
Start Over Author "Maruyama-Sakurai, Keiko"
25 results on '"Maruyama-Sakurai, Keiko"'

2. Factors associated with reversals of COVID-19 vaccination willingness: Results from two longitudinal, national surveys in Japan 2021-2022

Author

Ghaznavi, Cyrus, Yoneoka, Daisuke, Kawashima, Takayuki, Eguchi, Akifumi, Murakami, Michio, Gilmour, Stuart, Kaneko, Satoshi, Kunishima, Hiroyuki, Naito, Wataru, Sakamoto, Haruka, Maruyama-Sakurai, Keiko, Takahashi, Arata, Takayama, Yoshihiro, Tanoue, Yuta, Yamamoto, Yoshiko, Yasutaka, Tetsuo, Miyata, Hiroaki, and Nomura, Shuhei

Published
2022
Full Text
View/download PDF

3. Characterising reasons for reversals of COVID-19 vaccination hesitancy among Japanese people: One-year follow-up survey

Author

Nomura, Shuhei, Eguchi, Akifumi, Yoneoka, Daisuke, Murakami, Michio, Ghaznavi, Cyrus, Gilmour, Stuart, Kaneko, Satoshi, Kawashima, Takayuki, Kunishima, Hiroyuki, Naito, Wataru, Sakamoto, Haruka, Maruyama-Sakurai, Keiko, Takahashi, Arata, Takayama, Yoshihiro, Tanoue, Yuta, Yamamoto, Yoshiko, Yasutaka, Tetsuo, and Miyata, Hiroaki

Published
2022
Full Text
View/download PDF

5. Cost‐effectiveness of sodium‐glucose cotransporter‐2 inhibitors in the treatment of diabetic nephropathy in Japan.

Author

Maruyama‐Sakurai, Keiko, Tachimori, Hisateru, Saito, Eiko, Kohsaka, Shun, Segawa, Yasumasa, Miyata, Hiroaki, and Igarashi, Ataru

Subjects
*HEALTH insurance claims, *DIABETIC nephropathies, *MYOCARDIAL infarction, *SODIUM-glucose cotransporter 2 inhibitors, *OLDER patients
Abstract

Aim: To assess the cost‐effectiveness of diabetic nephropathy treatment with sodium‐glucose cotransporter‐2 (SGLT2) inhibitors in Japanese clinical practice, considering diabetes‐related complications. Materials and Methods: A population‐based Monte Carlo simulation was used to estimate the cost‐effectiveness for people with diabetic nephropathy who initiated pharmacotherapy with an SGLT2 inhibitor plus conventional treatment or conventional treatment alone, based on quality‐adjusted life‐years (QALYs) and healthcare costs. The Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation study (CREDENCE) and the Japanese Society for Dialysis Research statistical survey were the primary sources of probability and mortality, while Japanese Health Insurance Claims Data were the cost source. The state transition model included diabetic nephropathy, hospitalization due to cardiovascular disease, dialysis, and death. One‐way and probabilistic sensitivity analyses were used to explore model uncertainty. Results: Using the threshold of JPY 5 000 000 per QALY, SGLT2 inhibitor plus conventional treatment was more cost‐effective than conventional treatment alone, with an incremental cost‐effectiveness ratio of JPY 654 309 per QALY. Treating 100 000 people, SGLT2 inhibitor plus conventional treatment prevented 2234 deaths and reduced 5793 fewer heart failure cases, 3967 fewer myocardial infarctions and stroke events. Sensitivity analysis affirmed the robustness of these results for patients aged under 70 years. Conclusions: The SGLT2 inhibitor treatment appeared to be cost‐effective for the overall population of our study and particularly for younger patients (<70 years old). For older patients (≥70 years old), the cost‐effectiveness was less clear and may require further evaluation. Decision‐makers should consider this age‐based heterogeneity when making recommendations about SGLT2 inhibitor treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Characterizing Healthy Dietary Practices in Japan: Insights from a 2024 Nationwide Survey and Cluster Analysis

Author

Nomura, Shuhei, primary, Eguchi, Akifumi, additional, Maruyama-Sakurai, Keiko, additional, Higashino, Ruka, additional, Yoneoka, Daisuke, additional, Kawashima, Takayuki, additional, Tanoue, Yuta, additional, Kawamura, Yumi, additional, Kumar, Rauniyar Santosh, additional, Fujita, Takanori, additional, and Miyata, Hiroaki, additional

Published
2024
Full Text
View/download PDF

12. Characterizing Healthy Dietary Practices in Japan: Insights from a 2024 Nationwide Survey and Cluster Analysis of 27,154 Respondents

Author

Nomura, Shuhei, primary, Eguchi, Akifumi, additional, Maruyama-Sakurai, Keiko, additional, Higashino, Ruka, additional, Yoneoka, Daisuke, additional, Kawashima, Takayuki, additional, Tanoue, Yuta, additional, Kawamura, Yumi, additional, Santosh Kumar, Rauniyar, additional, Fujita, Takanori, additional, and Miyata, Hiroaki, additional

Published
2024
Full Text
View/download PDF

16. Factors associated with the risk perception of COVID-19 infection and severe illness: A cross-sectional study in Japan

Author

Adachi, Megumi, primary, Murakami, Michio, additional, Yoneoka, Daisuke, additional, Kawashima, Takayuki, additional, Hashizume, Masahiro, additional, Sakamoto, Haruka, additional, Eguchi, Akifumi, additional, Ghaznavi, Cyrus, additional, Gilmour, Stuart, additional, Kaneko, Satoshi, additional, Kunishima, Hiroyuki, additional, Maruyama-Sakurai, Keiko, additional, Tanoue, Yuta, additional, Yamamoto, Yoshiko, additional, Miyata, Hiroaki, additional, and Nomura, Shuhei, additional

Published
2022
Full Text
View/download PDF

17. Characterising Reasons for Reversals of COVID-19 Vaccination Hesitancy Among Japanese People: One-Year Follow-Up Survey

Author

Nomura, Shuhei, primary, Eguchi, Akifumi, additional, Yoneoka, Daisuke, additional, Murakami, Michio, additional, Ghaznavi, Cyrus, additional, Gilmour, Stuart, additional, Kaneko, Satoshi, additional, Kawashima, Takayuki, additional, Kunishima, Hiroyuki, additional, Naito, Wataru, additional, Sakamoto, Haruka, additional, Maruyama-Sakurai, Keiko, additional, Takahashi, Arata, additional, Takayama, Yoshihiro, additional, tanoue, yuta, additional, Yasutaka, Tetsuo, additional, Yamamoto, Yoshiko, additional, and Miyata, Hiroaki, additional

Published
2022
Full Text
View/download PDF

18. Additional file 2 of Tracking Japan’s development assistance for health, 2012–2016

Author

Nomura, Shuhei, Sakamoto, Haruka, Sugai, Maaya Kita, Nakamura, Haruyo, Maruyama-Sakurai, Keiko, Sangnim Lee, Ishizuka, Aya, and Shibuya, Kenji

Abstract

Additional file 2: Table S1. Development assistance for health by target region, 2012–2016 (2016 USD in million, %): (A) bilateral (loans), (B) bilateral (grants), (C) multilateral, (D) total. WHO: World Health Organization; UNAIDS: Joint United Nations Programme on HIV/AIDS; UNFPA: United Nations Population Fund; UNICEF: United Nations Children’s Fund; UNDP: United Nations Development Programme; AfDB: African Development Bank; AsDB: Asian Development Bank; IADB: Inter-American Development Bank; Global Fund: The Global Fund to Fight AIDS, Tuberculosis and Malaria; Gavi: Gavi, The Vaccine Alliance; JICA: Japan International Cooperation Agency. Other UN agencies include Food and Agriculture Organization (FAO), United Nations Relief and Works Agency for Palestine Refugees in the Near East (UNRWA), World Food Programme (WFP), etc. NGOs include International Planned Parenthood Federation, etc. Others include Global Environment Facility (GEF), etc. Table S2. Development assistance for health by channel, 2012–2016 (2016 USD in million, %). WHO: World Health Organization; UNAIDS: Joint United Nations Programme on HIV/AIDS; UNFPA: United Nations Population Fund; UNICEF: United Nations Children's Fund; UNDP: United Nations Development Programme; AfDB: African Development Bank; AsDB: Asian Development Bank; IADB: Inter-American Development Bank; Global Fund: The Global Fund to Fight AIDS, Tuberculosis and Malaria; Gavi: Gavi, The Vaccine Alliance; JICA: Japan International Cooperation Agency. Other UN agencies include Food and Agriculture Organization (FAO), United Nations Relief and Works Agency for Palestine Refugees in the Near East (UNRWA), World Food Programme (WFP), etc. NGOs include International Planned Parenthood Federation, etc. Others include Global Environment Facility (GEF), etc. Table S3. Developing assistance for health channeled through multilateral agencies, 2012–2016 (2016 USD in million, %). WHO: World Health Organization; UNAIDS: Joint United Nations Programme on HIV/AIDS; UNFPA: United Nations Population Fund; UNICEF: United Nations Children’s Fund; UNDP: United Nations Development Programme; AfDB: African Development Bank; AsDB: Asian Development Bank; IADB: Inter-American Development Bank; Global Fund: The Global Fund to Fight AIDS, Tuberculosis and Malaria; Gavi: Gavi, The Vaccine Alliance; JICA: Japan International Cooperation Agency. Other UN agencies include Food and Agriculture Organization (FAO), United Nations Relief and Works Agency for Palestine Refugees in the Near East (UNRWA), World Food Programme (WFP), etc. Table S4. Development assistance for health by health focus area, 2012–2016 (2016 USD in million, %): (A) bilateral (loans), (B) bilateral (grants), (C) multilateral, (D) total. STD: sexually transmitted disease. CRS purpose code: Basic health care = 12220; Basic health infrastructure = 12230; Basic nutrition = 12240; Health education = 12261; Health personnel development = 12281; Reproductive health care = 13020; Family planning = 13030; Infectious disease control = 12250; Malaria control = 12262; Tuberculosis control = 12263; STD control including HIV/AIDS = 13040; Health policy and administrative management = 12110; Medical education/training = 12181; Medical research = 12182; Medical services = 12191; Population policy and administrative management = 13010; Personnel development for population and reproductive health = 13081. Table S5. Development assistance for health for primary healthcare and health system strengthening, 2012–2016 (2016 USD in million, %): (A) bilateral (loans), (B) bilateral (grants), (C) multilateral, (D) total. PHC: public health care; HSS: health system strengthening. PHC definition #1 = Basic health care and infrastructure (CRS purpose codes: 12220, 12230, 12240, 12261, 12281); PHC definition #2 = Reproductive health care and family planning (13020, 13030); PHC definition #3 = Infectious disease control, including malaria and tuberculosis (12250, 12262, 12263); PHC definition #4 = Sexually transmitted disease (STD) control including HIV/AIDS (13040); Broader PHC definition = Definition #1 + #2 + #3 + #4; HSS definition #1 = Health policy, administration & management (12110); HSS definition #2 = Medical services, training & research (12181, 12182, 12191); HSS definition #3 = Population policy & administration (13010, 13081); Broader HSS definition = Definition #1 + #2 + #3.

Published
2021
Full Text
View/download PDF

19. Additional file 1 of Correction to: Tracking Japan’s development assistance for health, 2012–2016

Author

Nomura, Shuhei, Sakamoto, Haruka, Sugai, Maaya Kita, Nakamura, Haruyo, Maruyama-Sakurai, Keiko, Sangnim Lee, Ishizuka, Aya, and Shibuya, Kenji

Abstract

Additional file 2: Supplementary Table 1. Development assistance for health by target region, 2012–2016 (2016 USD in million, %): (A) bilateral (loans), (B) bilateral (grants), (C) multilateral, (D) total. Supplementary Table 2. Development assistance for health by channel, 2012–2016 (2016 USD in million, %). Supplementary Table 3. Developing assistance for health channeled through multilateral agencies, 2012–2016 (2016 USD in million, %). Supplementary Table 4. Development assistance for health by health focus area, 2012–2016 (2016 USD in million, %): (A) bilateral (loans), (B) bilateral (grants), (C) multilateral, (D) total. Supplementary Table 5. Development assistance for health for primary healthcare and health system strengthening, 2012–2016 (2016 USD in million, %): (A) bilateral (loans), (B) bilateral (grants), (C) multilateral, (D) total.

Published
2021
Full Text
View/download PDF

22. Additional file 1 of Tracking Japan’s development assistance for health, 2012–2016

Author

Nomura, Shuhei, Sakamoto, Haruka, Sugai, Maaya Kita, Nakamura, Haruyo, Maruyama-Sakurai, Keiko, Sangnim Lee, Ishizuka, Aya, and Shibuya, Kenji

Abstract

Additional file 1: Figure S1. Developing assistance for health channeled through multilateral agencies, 2012–2016. WHO: World Health Organization; UNAIDS: Joint United Nations Programme on HIV/AIDS; UNFPA: United Nations Population Fund; UNICEF: United Nations Children’s Fund; UNDP: United Nations Development Programme; AfDB: African Development Bank; AsDB: Asian Development Bank; IADB: Inter-American Development Bank; Global Fund: The Global Fund to Fight AIDS, Tuberculosis and Malaria; Gavi: Gavi, The Vaccine Alliance.

Published
2020
Full Text
View/download PDF

23. Determinants of the Implementation of Home Evaluations among Patients with Fall-Related Fractures at a Convalescent Rehabilitation Ward in Tokyo: A Cross-Sectional Study.

Author

Tsuchiya-Ito, Rumiko, Kusumoto, Naoki, Maruyama-Sakurai, Keiko, Tamai, Anna, Yokoyama, Haruko, Watanabe, Ayako, Fujiwara, Takuya, and Yamanaka, Takashi

Subjects
CONFIDENCE intervals, MULTIPLE regression analysis, REGRESSION analysis, CONCEPTUAL structures, T-test (Statistics), HOSPITAL wards, ACCIDENTAL falls, CHI-squared test, RESEARCH funding, HOUSING, ODDS ratio, DATA analysis software, BONE fractures, SECONDARY analysis
Abstract

Home adaptations are integral for inpatients with fall-related fractures, especially during discharge. However, it is unclear as to how patient-implemented home evaluations can be prioritized with limited professional rehabilitation resources. This study examines the associations between predisposing, enabling, and needs factors with the implementation of home evaluations in the eastern district of Tokyo. Being a female and lower comprehension in cognitive function was significantly associated with the implementation of home evaluations. It may be necessary to consider patients' cognitive function when deciding who to target for housing evaluations and to seek strategies to best estimate their needs. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

25. Trust in governments, public health institutions, and other information sources as determinants of COVID-19 vaccine uptake behavior in Japan.

Author

Cao, Alton, Ueta, Mami, Uchibori, Manae, Murakami, Michio, Kunishima, Hiroyuki, Santosh Kumar, Rauniyar, Prommas, Prapichaya, Tomoi, Hana, Gilmour, Stuart, Sakamoto, Haruka, Hashizume, Masahiro, Naito, Wataru, Yasutaka, Tetsuo, Maruyama-Sakurai, Keiko, Miyata, Hiroaki, and Nomura, Shuhei

Subjects
*HEALTH facilities, *VACCINATION status, *COVID-19 vaccines, *COMMUNICABLE diseases, *INFORMATION resources
Abstract

Trust in governments and public institutions as a determinant of public health outcomes has gained increased attention since the COVID-19 pandemic. Provided historically low confidence in vaccines in Japan, investigating the role of trust in information sources and actual COVID-19 vaccination uptake behavior will be invaluable for future vaccine promotion policymaking. Therefore, the objective of this study was to elucidate the determinants of COVID-19 vaccination uptake and evaluate the relationship between trust in different information sources and COVID-19 vaccination behavior in Japan. For this study, we leveraged a longitudinal series of web-based surveys of 19,174 individuals in Japan conducted between 2021 and 2022 which asked questions regarding a wide range of sociodemographic and psychographic characteristics related to the COVID-19 pandemic. Determinant analysis for vaccination (at least one dose of a COVID-19 vaccine) was conducted via multiple logistic regression, and odds ratios (OR) with 95% confidence intervals (CI) were estimated. After adjustment for sociodemographic determinants of vaccine uptake, aggregate trust in the systems and institutions of vaccine approval (OR: 1.42, 95% CI: 1.30–1.56), and trust in information about the COVID-19 pandemic coming from government sources (OR: 1.27, 95% CI: 1.12–1.44) were found to be consistently powerful predictors of COVID-19 vaccination. Trust in media sources including traditional media (OR: 1.21, 95% CI: 1.07–1.36), and the internet (OR: 0.77, 95% CI: 0.66–0.89) had significant and opposing effects. Our findings support the broader hypothesis that trust in governments and public health institutions remains a powerful determinant for COVID-19 vaccine uptake in Japan. We also found that vaccination decision-making is a multifactorial process that includes the synthesis of trust in public institutions and media, and its interaction with psychosocial determinants such as prosociality and health literacy. We hope to apply this study's findings towards future vaccine programs for contagious diseases. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results